1.	A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: HuLuc63-1703, 2007-006677-83, NCT00742560
2.	Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: HuLuc63-1701, FHCRC-2127.00, PDL-HuLuc63-1701, NCT00425347
3.	Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA204-005, NCT01241292